Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status

PURPOSE: The AVAglio trial established the beneficial effect of add-on bevacizumab (BEV) for the treatment of newly diagnosed glioblastomas (nd-GBMs) that led to the approval of BEV for the treatment of these patients in Japan. However, the rationality of using BEV as a first-line treatment for nd-G...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Nobuhiro, Yoshimoto, Koji, Hatae, Ryusuke, Kuga, Daisuke, Akagi, Yojiro, Sangatsuda, Yuhei, Suzuki, Satoshi O, Shono, Tadahisa, Mizoguchi, Masahiro, Iihara, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261854/
https://www.ncbi.nlm.nih.gov/pubmed/28176936
http://dx.doi.org/10.2147/OTT.S125587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261854/
https://www.ncbi.nlm.nih.gov/pubmed/28176936
http://dx.doi.org/10.2147/OTT.S125587

Ejemplares similares